Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Calcium phosphate nanoparticle adjuvant.

Q He1, A R Mitchell, S L Johnson

  • 1BioSante Pharmaceuticals, Inc., Smyrna, Georgia 30082, USA. biosante@bellsouth.net

Clinical and Diagnostic Laboratory Immunology
|November 4, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Potential involvement of placental AhR in unexplained recurrent spontaneous abortion.

Reproductive toxicology (Elmsford, N.Y.)·2015
Same author

c-Abl-p38α signaling plays an important role in MPTP-induced neuronal death.

Cell death and differentiation·2015
Same author

Interleukin-10 gene promoter region polymorphisms are not associated with BCG osteitis in vaccinated infants.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2015
Same author

Cloning, molecular characterization, and expression pattern of FGF5 in Cashmere goat (Capra hircus).

Genetics and molecular research : GMR·2015
Same author

Metabolic syndrome, inflammation and lower urinary tract symptoms: possible translational links.

Prostate cancer and prostatic diseases·2015
Same author

Silencing FKBP38 gene by siRNA induces activation of mTOR signaling in goat fetal fibroblasts.

Genetics and molecular research : GMR·2015
Same journal

Longitudinal analysis of Severe Acute Respiratory Syndrome (SARS) coronavirus-specific antibody in SARS patients.

Clinical and diagnostic laboratory immunology·2005
Same journal

Immunoglobulin E binding reactivity of a recombinant allergen homologous to alpha-Tubulin from Tyrophagus putrescentiae.

Clinical and diagnostic laboratory immunology·2005
Same journal

Unidirectional suppression of Anaplasma phagocytophilum genotypes in infected lambs.

Clinical and diagnostic laboratory immunology·2005
Same journal

Long-term follow-up of Hepatitis B Surface antibody levels in subjects receiving universal Hepatitis B vaccination in infancy in an area of hyperendemicity: correlation between radioimmunoassay and enzyme immunoassay.

Clinical and diagnostic laboratory immunology·2005
Same journal

Gamma interferon is dispensable for neopterin production in vivo.

Clinical and diagnostic laboratory immunology·2005
Same journal

Induction of antigen-specific Th1-type immune responses by gamma-irradiated recombinant Brucella abortus RB51.

Clinical and diagnostic laboratory immunology·2005
See all related articles

A novel calcium phosphate (CAP) nanoparticle adjuvant shows enhanced immunity against viral infections compared to aluminum adjuvants. CAP demonstrates superior potency, reduced inflammation, and a favorable safety profile in animal models.

Area of Science:

  • Immunology
  • Vaccinology
  • Nanotechnology

Background:

  • Adjuvants enhance vaccine efficacy by stimulating immunoregulatory responses.
  • Current adjuvants like aluminum (alum) can elicit inflammatory responses and undesirable IgE antibody production.

Purpose of the Study:

  • To evaluate a novel calcium phosphate (CAP) nanoparticulate adjuvant against alum for inducing immunity to herpes simplex virus type 2 (HSV-2) and Epstein-Barr virus (EBV).

Main Methods:

  • A murine model was used to compare the immunogenicity and efficacy of CAP and alum adjuvants.
  • Immune responses, including antibody titers (IgG2a, IgE, neutralizing antibodies) and protection rates, were assessed.

Main Results:

  • CAP demonstrated greater adjuvant potency than alum.

Related Experiment Videos

  • CAP elicited minimal inflammation, induced high IgG2a and neutralizing antibody titers, and provided significant protection against HSV-2.
  • CAP resulted in an insignificant IgE response, unlike alum.

    • Conclusions:

    • Calcium phosphate (CAP) nanoparticulate adjuvant is a potent and well-tolerated alternative to alum.
    • CAP's favorable immunogenicity and safety profile suggest its potential for human vaccine applications.